VTP50469 is a novel, orally available menin-MLL1 inhibitor effective against MLL-rearranged and NPM1-mutant leukemia Meeting Abstract
| Authors: | Krivtsov, A. V.; Eschle, B. K.; Witkin, M.; Gadrey, J. Y.; Uckelmann, H. J.; Kitajima, S.; McGeehan, G. M.; Armstrong, S. A. |
| Abstract Title: | VTP50469 is a novel, orally available menin-MLL1 inhibitor effective against MLL-rearranged and NPM1-mutant leukemia |
| Meeting Title: | 109th Annual Meeting of the American Association for Cancer Research (AACR) |
| Journal Title: | Cancer Research |
| Volume: | 78 |
| Issue: | 13 Suppl. |
| Meeting Dates: | 2018 Apr 14-18 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0008-5472 |
| Publisher: | American Association for Cancer Research |
| Date Published: | 2018-07-01 |
| Language: | English |
| ACCESSION: | WOS:000468819503568 |
| DOI: | 10.1158/1538-7445.Am2018-4958 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 4958 -- Source: Wos |
